We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $47.60, moving -5.52% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.14%. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.38%.
The company's shares have seen a decrease of 21.55% over the last month, not keeping up with the Medical sector's loss of 1.94% and the S&P 500's gain of 5.35%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on August 4, 2025. The company is predicted to post an EPS of $0.18, indicating a 200% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $551.84 million, indicating a 74.83% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.75 per share and a revenue of $2.35 billion, signifying shifts of +177.78% and +58.88%, respectively, from the last year.
Any recent changes to analyst estimates for Hims & Hers Health, Inc. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.27% rise in the Zacks Consensus EPS estimate. Hims & Hers Health, Inc. currently has a Zacks Rank of #1 (Strong Buy).
Digging into valuation, Hims & Hers Health, Inc. currently has a Forward P/E ratio of 67.48. This represents a premium compared to its industry average Forward P/E of 26.73.
We can also see that HIMS currently has a PEG ratio of 1.85. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical Info Systems was holding an average PEG ratio of 3.14 at yesterday's closing price.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $47.60, moving -5.52% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.14%. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.38%.
The company's shares have seen a decrease of 21.55% over the last month, not keeping up with the Medical sector's loss of 1.94% and the S&P 500's gain of 5.35%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on August 4, 2025. The company is predicted to post an EPS of $0.18, indicating a 200% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $551.84 million, indicating a 74.83% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.75 per share and a revenue of $2.35 billion, signifying shifts of +177.78% and +58.88%, respectively, from the last year.
Any recent changes to analyst estimates for Hims & Hers Health, Inc. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.27% rise in the Zacks Consensus EPS estimate. Hims & Hers Health, Inc. currently has a Zacks Rank of #1 (Strong Buy).
Digging into valuation, Hims & Hers Health, Inc. currently has a Forward P/E ratio of 67.48. This represents a premium compared to its industry average Forward P/E of 26.73.
We can also see that HIMS currently has a PEG ratio of 1.85. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical Info Systems was holding an average PEG ratio of 3.14 at yesterday's closing price.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.